info@seagull-health.com
SeagullHealth
语言:
search
new
Indication of Qlosi Eye Drops
503
Article source: Seagull Pharmacy
Sep 19, 2025

Qlosi Eye Drops is a cholinergic agonist ophthalmic solution developed by Orasis Pharmaceuticals, intended for the treatment of presbyopia. As an innovative ophthalmic medication, Qlosi improves near vision through a unique mechanism of action, providing a convenient treatment option for patients with presbyopia.

Indication of Qlosi Eye Drops

Primary Therapeutic Use

The primary indication of Qlosi Eye Drops is the treatment of presbyopia in adults.

Presbyopia is an age-related visual impairment characterized by the gradual loss of the eye's ability to focus on near objects, typically onset around the age of 40.

Through the action of its active ingredient, Pilocarpine Hydrochloride, Qlosi can temporarily improve near vision, providing functional visual improvement for presbyopic patients.

Specification and Characteristic of Qlosi Eye Drops

Dosage Form and Specification

Qlosi is a sterile, clear, colorless to slightly yellow, slightly viscous ophthalmic solution.

Active ingredient: Pilocarpine Hydrochloride 0.4% (equivalent to 4mg/mL).

Packaging form: Single-use vials, with a filling volume of 0.4mL per vial.

Chemical name: (3S-cis)-3-Ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone monohydrochloride.

Molecular weight: 244.72g/mol.

Molecular formula: C₁₁H₁₆N₂O₂·HCl.

Composition

Active ingredient: Pilocarpine Hydrochloride (4mg per mL).

Excipients:

Hypromellose.

Sodium Chloride.

Sodium Hyaluronate.

Disodium Edetate Dihydrate.

Water for Injection.

May contain Sodium Hydroxide and/or Hydrochloric Acid for pH adjustment.

Storage Method of Qlosi Eye Drops

Storage Condition Requirements

Unopened products: Store refrigerated at 2°C to 8°C (36°F to 46°F).

Opened aluminum foil pouches: Once the aluminum foil pouch is opened, individual single-use vials can be stored at room temperature (not exceeding 25°C/77°F) but must be used within 30 days.

Protect from light: All products should be kept away from direct light exposure.

Single-use only: Once a vial is opened, it should be used immediately. Any remaining solution must be discarded and cannot be reused.

Precautions for Use

Administration method: Use a maximum of twice daily, 1 drop per eye each time, with an interval of 2-3 hours between the two administrations.

Contact lens use: Remove contact lenses before instilling the drops; wait at least 10 minutes after instillation before reinserting the contact lenses.

Concomitant medication: If other eye medications need to be used, an interval of at least 5 minutes should be maintained between their administration and that of Qlosi.

Contamination prevention: Avoid touching the eye or any surface with the vial tip to prevent contamination.

Special reminder for patients: Temporary blurred vision or decreased night vision may occur after using Qlosi. Patients should exercise caution when driving at night or engaging in hazardous activities in low-light environments. If flashes of light, floaters, or sudden vision loss occur, seek medical attention for examination immediately.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
What Are the Side Effects of Cabotegravir?
Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that must be used in combination with Rilpivirine (EDURANT). It is indicated for the short-term treatment of virologically suppress...
How to Use Cabotegravir
Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that must be used in combination with Rilpivirine. It is indicated for the short-term treatment of virologically suppressed adult p...
How to Use Emicizumab
Emicizumab is a bispecific monoclonal antibody used for the treatment of hemophilia A with inhibitors. It restores blood coagulation function by bridging factors IXa and X.How to Use EmicizumabRoute o...
What Are the Side Effects of Ramelteon?
Ramelteon is mainly used for the treatment of onset insomnia (difficulty falling asleep). It regulates the sleep-wake cycle by mimicking endogenous melatonin.What Are the Side Effects of Ramelteon?1. ...
Indication of Etrasimod
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator developed by ViiV Healthcare, which was first approved in the United States in 2023. As a novel oral medication for the treatment of ulc...
Conventional Dosage and Administration
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of moderate to severe active ulcerative colitis (UC) in adults.How to Use EtrasimodConventional Dosage and A...
Etrasimod: Precautions and Monitoring for Medication Use
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator indicated for the treatment of moderate to severe active ulcerative colitis (UC) in adults.Etrasimod: Precautions and Monitoring for Med...
What Is the Therapeutic Efficacy of Etrasimod?
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator. It was approved for marketing by the U.S. FDA in 2023 for the treatment of moderate to severe active ulcerative colitis (UC) in adults....
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved